U.S. Markets open in 7 hrs 15 mins

# Insmed Incorporated (INSM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
17.35+0.11 (+0.64%)
At close: 4:00PM EDT
People also watch
GNVCCRISIMMUBCRXIMGN
• IdiotInvestorvillage bd FAKE NEWS ! zake1".Maybe we will see a Sub Part H approval in the next few months, rather than being forced to wait until Sept, or Oct." \Maybe the poor fellow meant 2018\?\dont understand the process \revenues when?\ this is important to have an understanding of submission and review to assess investment timing\approximate review results and revenue timeline has been posted and deleted by those who push Insmed Fake News\idiotvillage STAY THERE!\
• Options : Open interest in Oct puts at 15 strike price is huge : 4464 (i.e., involving 446,400 shares). In net effect, bets being made that INSM share price will either be above or below $9 at October expiration. (current premium is approx.$6)
• 10M @$17 would be a nice cushion into results • Yesterdays ASM was everything management could ask for No one was there. Approved the Insmed Incorporated 2017 Incentive Plan.Management basically gets tons of shares for NOTHING Will shareholders get sold down the drain while a few make tons of money? Lewis is a former business manager not a scientist educator or doctor.Lewis will take a promotion to a big pharma with the deal.Hes just biding his time • Aridigm sues Insmeds patents = LEGAL PROCEEDINGS On May 1, 2017, the Company filed a post grant review, or a PGR, petition in the United States Patent and Trademark Office Patent Trial and Appeal Board, or PTAB, challenging the validity of all 26 claims of U.S. Patent No.9,402,845 or the ‘845 Patent, assigned to Insmed Incorporated, or Insmed. The ‘845 Patent issued on August 2, 2016, and is entitled “Lipoid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof.” PGR is a proceeding that became available in September 2012 in accordance with the America Invents Act. In a PGR, a petitioner may request that PTAB reconsider the validity of issued patent claims. Any patent claim PTAB determines to be unpatentable is stricken from the challenged patent. Once PTAB assigns a filing date to the Company’s PGR petition, Insmed will have 3 months to file an optional Preliminary Response. Then, within 3 months of Insmed’s Preliminary Response due date, PTAB will decide whether to institute post grant review of the ‘845 Patent. If the PGR is instituted, PTAB should issue a Final Written Decision addressing validity of patent claim(s) within 18 months of the filing date. • Sub Part H approval should take 9 months from results with a little luck • Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced the appointment of Paolo Tombesi as Chief Financial Officer, effective June 1, 2017, and Paul Streck, M.D., as Chief Medical Officer, effective June 5, 2017. Additionally, Eugene Sullivan, M.D., has been appointed to the newly created role of Chief Product Strategy Officer. • waiting for below$16 to buy
$15.40 would be the bomb Trump slump underway • \ from the 10Q\The Parent is no longer developing the Iplex product, and has no present intention of resuming such development. " \ doesnt matter to the Idiot village board\ • Insmed holding up better than all biotechs.by just staying even • I sure am glad I did not listen to the basher Terry at$7. I am up over 130%
• good company ,good team it will come back
• It is time to face the truth. This is stock is WINNING.
• INSM will move with the market untill News
Not so hard to understand.
The dilution doe not sound like something they would need to do if the results are good
Patiently waiting till Fall.
• Attention all bagholders.........you are all losers. BK within 2 years!!!! INSM was $29 two years ago......a total criminal fraud!!!!!!!! SELLLLLL! • Terry-Insmed is voicing some INSM issues elsewhere.He has no Yahoo account Kathy {kinkey} posted a couple of his recent points {with additional yanking} "One piece of recent information you may want to be aware of and that will not be mentioned by Insmed,Inc is that coverage of pre-existing conditions is at risk .This will affect reimbursement revenues to the patient population Insmed hopes to serve. NTM and Cystic Fibrosis groups have issued statements against this possible change. Insmeds Arikayce is supposed to be priced very high This issue will not affect the SP or investing until 2019 should all go well and the owner is out in the real world." - Terry still thinks Insmed is "a good "bet - short term financial " but most traders are playing it safe until they see the outcome of the Phase3 trial.Terry moved his speculative release date out from August to October ,not a great time for the market to react.He outlined an investment strategy for current holders but I will not re-post it. Evidently Yahoo plans to drop these boards. Sayonara comment on H.C. Wainwright analyst Andrew Fein price target of$35. - " l o l ! .Who would believe such a thing?
When an analyst says a double! watch your wallet.
• Very sad really\The idiot investor village board without regards to medicine or investment\ is a bunch of fools trying to convince one another that the obvious failure of the drug IPLEX somehow has a future\
\the board speaks to just a few that find comfort from a greater fool\
Had iplex had any future\it would have been known many years ago.
• Joe:Why are Insmeds number of patients wrong?\ Joe: the numbers at the EC \ are Not the patients Arikayce will address.\They are numbers of the whole spectrum of NTM \hence they are misleading\ Arikayce will be a Add On therapy to patients that fail common antibiotic treatments\ (that are at a much lower cost)\ These critical or "refractory " patient numbers may be increasing but Nowhere near the numbers Insmed flowered upon the Investor idiot board who are readers not investors\ Lewis did a good job \I mean did a good SnowJob
• Leerick for idiots "Insmed price target raised to $27 from$21 at Leerink,
\this is for the village idiots \Lerrick analyst raised the price on hot air.\Nothing has changed \ \Joey Schwartz said it " reflect Q1 net income/EPS and management's current estimates for the refractory NTM opportunity. "
*** for idiots ** Insmed has no revenues ****** or estimates for the "opportunity"\
\ Joey the goes onto to sees a positive outcome surrounding INS-1007\
\All Insmed has are "plans" INS-1007
\Joey reiterates an Outperform rating on the shares \
Since Joey initially gave a Outperform rating\ INSM has Under performed \